GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Scaled Net Operating Assets

GB Sciences (GB Sciences) Scaled Net Operating Assets : -14.32 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GB Sciences's operating assets for the quarter that ended in Dec. 2023 was $0.13 Mil. GB Sciences's operating liabilities for the quarter that ended in Dec. 2023 was $3.48 Mil. GB Sciences's Total Assets for the quarter that ended in Sep. 2023 was $0.23 Mil. Therefore, GB Sciences's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -14.32.


GB Sciences Scaled Net Operating Assets Historical Data

The historical data trend for GB Sciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Scaled Net Operating Assets Chart

GB Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.31 0.15 -0.06 -1.22

GB Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -1.12 -9.30 -14.39 -14.33

Competitive Comparison of GB Sciences's Scaled Net Operating Assets

For the Biotechnology subindustry, GB Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where GB Sciences's Scaled Net Operating Assets falls into.



GB Sciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GB Sciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2023 )
=(Operating Assets (A: Mar. 2023 )-Operating Liabilities (A: Mar. 2023 ))/Total Assets (A: Mar. 2022 )
=(0.242-3.364)/2.55
=-1.22

where

Operating Assets(A: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.352 - 0.11
=0.242

Operating Liabilities(A: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.76 - 0 - 1.396
=3.364

GB Sciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(0.13-3.482)/0.234
=-14.32

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.147 - 0.017
=0.13

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.994 - 0.075 - 1.437
=3.482

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GB Sciences Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of GB Sciences's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences (GB Sciences) Business Description

Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences (GB Sciences) Headlines

From GuruFocus

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

By GuruFocusNews GuruFocusNews 12-06-2021